{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-26-005316","form_type":"8-K","ticker":"CLDX","cik":"0000744218","company_name":"Celldex Therapeutics, Inc.","filed_at":"2026-08-06T20:01:21+00:00","discovered_at":"2026-08-06T20:02:20.560914+00:00","generated_at":"2026-08-06T20:02:28.520001+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Celldex Q2 net loss $73.5M; barzolvolimab Phase 3 CSU topline data expected Sept/Oct 2026","bullets":["Net loss of $73.5M ($0.94/share) vs $56.6M in Q2 2025; no material revenue.","Cash $717.6M after $323.8M public offering; runway through 2028.","Barzolvolimab Phase 3 CSU enrolled 1,939 patients; topline data Sept/Oct 2026; BLA planned 2027.","Phase 2 prurigo nodularis study failed primary endpoints; discontinued.","CDX-622 Phase 1 showed rapid tryptase reduction; asthma POM study ongoing; expanding into allergic rhinitis and food allergy."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-005316","json":"https://secwatch.observer/filing/0001171843-26-005316.json","markdown":"https://secwatch.observer/filing/0001171843-26-005316.md","text":"https://secwatch.observer/filing/0001171843-26-005316.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/744218/000117184326005316/0001171843-26-005316-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/744218/000117184326005316/f8k_080626.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T20:02:28.520001+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}